AbbVie has completed the acquisition of ImmunoGen for $10.1bn, a move that significantly bolsters its oncology pipeline with promising treatments for solid tumours and haematologic malignancies.

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

关于ELAHERE ELAHERE为中美华东与ImmunoGen, Inc.（目前已被AbbVie收购）合作开发的针对叶酸受体α（FRα，一种在卵巢癌中高表达的细胞表面蛋白）靶点的 ...

Learn more about Christopher Missling, PhD, on LinkedIn and explore the innovative work of Anavex Life Sciences at their website. In the relentless pursuit of solutions for neurodegenerative diseases ...